Alvine strives to get affordable drugs for hypertension in Cameroon
This month like the previous ones, Alvine Nyintché is visiting the Etoug-Ebe Baptist Hospital in Yaounde. Aged 50, Alvine has been diagnosed with high blood pressure seven years ago.
“Most Cameroonians do not have medical insurance. Today, I pay 800 francs CFA every month for my hypertension treatment (about USD 1.5), whereas just a few months back, it cost me 5000 CFA francs. I am a single mother. My two daughters are unemployed and we have to pay rent,” says Alvine, who lives in Briqueterie, one of the largest slums of the Cameroonian capital.
Following the G20, Joerg Reinhardt, Chairman of the Novartis Board of Directors, reflects on how to fight rising antimicrobial resistance
ZURICH, Switzerland, July 20, 2017/3BL Media/ – Two weeks ago, G20 leaders committed to working together to address one of the world’s most pressing and perplexing security threats: antimicrobial resistance (AMR) – a fierce and evolving adversary against which conventional therapeutic weapons are of no use.
Novartis reaches agreement with Uganda to supply medicines that address the rapid rise of chronic diseases in the country. Uganda becomes the fifth country to launch the Novartis Access program.
July 6, 2017 /3BL Media/ -- We are pleased to announce that Novartis and the Ministry of Health of Uganda have signed a Memorandum of Understanding to implement Novartis Access in Uganda. Novartis Access medicines will be made available to patients in public health facilities through the National Medical Stores and through faith-based health services. The program will also cover capacity-building activities, including NCD prevention, diagnosis and treatment.
Pharmaceutical companies have long experience in measuring the impact of their business programs. The same should apply to their access-to-medicine efforts
Richard Laing, from the Boston University (BU) School of Public Health and former World Health Organization official, says that many efforts to expand access to medicines fail to gather sufficient evidence on how effective they are. His team at BU recently issued a study highlighting these gaps, and emphasizing the need for companies to better document the impact of their programs.
Novartis reaches agreement with Pakistan to supply medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation.
May 12, 2017 /3BL Media/ -- We are pleased to announce that Novartis and the Ministry of National Health Services, Regulation and Coordination of the Islamic Republic of Pakistan have signed a Memorandum of Understanding to implement Novartis Access in Pakistan. Novartis Access medicines will be made available to the poorest population through hospitals under the Prime Minister’s National Health Insurance Program.
More than half the ASEAN region’s 630 million people are under age 30. Harald Nusser, Head of Novartis Social Business, says that to fight the rise of chronic disease in South East Asia we need to inform its youth on the importance of healthy lifestyles.
As WEF Africa gets underway, Harald Nusser, Head of Novartis Social Business, emphasizes how novel solutions between the public and the private sector are needed to effectively fight the rising epidemic of chronic diseases in Africa
We all agree we need partnerships between the public and the private sector to meet the Sustainable Development Goals. Public-private partnerships (PPPs) require a better understanding between partners and innovation around institutional structures to ensure accountability, risk and benefit sharing, and value for money. These are fine words but, as the representative of a large, research-based multinational, I have found that things are not always that simple...